Status:
COMPLETED
Efficacy and Safety of Remimazolam Compared With Midazolam During Bronchoscopy:Randomised Controlled Trial
Lead Sponsor:
Chungbuk National University Hospital
Conditions:
Bronchoscopy
Remimazolam
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Objectives: Although remimazolam is an ultra-short-acting benzodiazepine with a shorter elimination half-life and faster recovery time than midazolam, studies evaluating its safety and efficacy during...
Eligibility Criteria
Inclusion
- aged ≥18 years who required diagnostic or therapeutic bronchoscopy and agreed to participate
Exclusion
- 1\) pregnancy, 2) moderate-to-severe hepatic impairment and lactose intolerance 3) mechanical ventilation 4) history of tracheostomy 5) poor patient cooperation
Key Trial Info
Start Date :
April 14 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 15 2023
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05994547
Start Date
April 14 2022
End Date
June 15 2023
Last Update
August 16 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chungbuk National University Hospital
Cheongju-si, North Chungcheong, South Korea, 28644